Utah Medical Products Hits New 52-Week High of $71.64

Utah Medical Products, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 71.64 on April 17, 2026. This achievement marks a notable increase from its 52-week low of USD 51.26, reflecting a year-over-year performance of 4.68%. The company, with a market capitalization of USD 205 million, operates with a price-to-earnings (P/E) ratio of 18.00, indicating its valuation relative to earnings. Additionally, Utah Medical Products boasts an impressive dividend yield of 108.47%, which stands out in the industry. The company's financial health is further illustrated by a negative debt-to-equity ratio of -0.71 and a return on equity of 9.46%, suggesting effective management of resources. While the broader S&P 500 has outperformed with a 34.89% gain over the same period, Utah Medical Products' recent price movement highlights its position within the market and the ongoing developments in its operational landscape.